Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meredith R Clark

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
AIDS and Behavior|November 8, 2019
Efficacy is Not Everything: Eliciting Women's Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice ExperimentErica N Browne, Elizabeth T Montgomery, Carol Mansfield, et al.
The Journal of Infectious Diseases|December 4, 2025
Partial post-exposure protection by topical inserts containing tenofovir alafenamide fumarate/elvitegravir in a macaque model of rectal SHIV infectionNatalia Makarova, Tyana Singletary, M Melissa Peet, et al.
Antimicrobial Agents and Chemotherapy|November 30, 2011
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ringJohn A Moss, Amanda M Malone, Thomas J Smith, et al.
Antimicrobial Agents and Chemotherapy|September 26, 2012
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxisTodd J Johnson, Meredith R Clark, Theodore H Albright, et al.
Ebiomedicine|November 7, 2022
Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaquesNatalia Makarova, Tyana Singletary, M Melissa Peet, et al.
AIDS and Behavior|June 27, 2020
Preferences and Acceptability of Vaginal Delivery Forms for HIV Prevention Among Women, Male Partners and Key Informants in South Africa and Zimbabwe: Qualitative FindingsPetina Musara, Cecilia Milford, Mary Kate Shapley-Quinn, et al.
The Journal of Infectious Diseases|December 22, 2023
Extended Postexposure Protection Against Vaginal Simian/Human Immunodeficiency Virus Infection With Tenofovir Alafenamide Fumarate/Elvitegravir Inserts in MacaquesNatalia Makarova, Tyana Singletary, M Melissa Peet, et al.
Ebiomedicine|November 24, 2022
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaquesCharles W Dobard, M Melissa Peet, Kenji Nishiura, et al.
Plos One|June 29, 2018
Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in womenAndrea Ries Thurman, Jill L Schwartz, Vivian Brache, et al.
Plos One|October 10, 2022
Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 studyAndrea R Thurman, Vivian Brache, Leila Cochon, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
AIDS and Behavior|November 8, 2019
Efficacy is Not Everything: Eliciting Women's Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice ExperimentErica N Browne, Elizabeth T Montgomery, Carol Mansfield, et al.
The Journal of Infectious Diseases|December 4, 2025
Partial post-exposure protection by topical inserts containing tenofovir alafenamide fumarate/elvitegravir in a macaque model of rectal SHIV infectionNatalia Makarova, Tyana Singletary, M Melissa Peet, et al.
Antimicrobial Agents and Chemotherapy|November 30, 2011
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ringJohn A Moss, Amanda M Malone, Thomas J Smith, et al.
Antimicrobial Agents and Chemotherapy|September 26, 2012
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxisTodd J Johnson, Meredith R Clark, Theodore H Albright, et al.
Ebiomedicine|November 7, 2022
Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaquesNatalia Makarova, Tyana Singletary, M Melissa Peet, et al.
AIDS and Behavior|June 27, 2020
Preferences and Acceptability of Vaginal Delivery Forms for HIV Prevention Among Women, Male Partners and Key Informants in South Africa and Zimbabwe: Qualitative FindingsPetina Musara, Cecilia Milford, Mary Kate Shapley-Quinn, et al.
The Journal of Infectious Diseases|December 22, 2023
Extended Postexposure Protection Against Vaginal Simian/Human Immunodeficiency Virus Infection With Tenofovir Alafenamide Fumarate/Elvitegravir Inserts in MacaquesNatalia Makarova, Tyana Singletary, M Melissa Peet, et al.
Ebiomedicine|November 24, 2022
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaquesCharles W Dobard, M Melissa Peet, Kenji Nishiura, et al.
Plos One|June 29, 2018
Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in womenAndrea Ries Thurman, Jill L Schwartz, Vivian Brache, et al.
Plos One|October 10, 2022
Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 studyAndrea R Thurman, Vivian Brache, Leila Cochon, et al.
Pageof 5